RxDoctor Payments DataLook up a doctor →

Ronald Zolty, MD

Cardiovascular Disease · Omaha, NENPI 1023108701

Payments from drug & device makers

$6,284,337in general payments, 2019–2025

Across 1,431 payments — averaging $4391.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3.1M
  • United Therapeutics Corporation$772K
  • Alnylam Pharmaceuticals Inc.$461K
  • Astrazeneca UK Limited$417K
  • Janssen Research & Development, LLC$414K
  • Actelion Pharmaceuticals US, Inc.$409K
  • plus $679K from 14 others
$1,890in research payments, 2019–2025

Across 8 payments — averaging $236.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$2K

What the payments were for

  • Consulting fees$95,68510%
  • Speaking & faculty fees$705,99175%
  • Travel & lodging$113,39312%
  • Food & beverage$29,8053%
  • Education$2000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,284,337 in reported general payments places this provider in the 95th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$111,361
Medicare patients
289
Services billed
1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat424$5,755,842
UptraviSelexipag230$5,455,775
OpsumitMacitentan117$1,475,657
Tyvaso DpiTreprostinil57$1,442,760
Orenitram ErTreprostinil Diolamine60$628,162
WinrevairSotatercept-Csrk32$566,378
FarxigaDapagliflozin Propanediol451$471,620
EntrestoSacubitril/Valsartan346$375,986
RemodulinTreprostinil Sodium16$281,422
Ambrisentan30$236,177
OzempicSemaglutide169$162,367
EliquisApixaban110$131,631
JardianceEmpagliflozin99$99,828
Sildenafil Citrate263$50,134
XareltoRivaroxaban34$33,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$409,301$6,931,432347 claims
BayerAdempas$177,592$5,755,842424 claims
MerckWinrevair$3,132,416$566,37832 claims
AstraZenecaFarxiga$140$471,620451 claims
NovartisEntresto$124,658$375,986346 claims
United Therapeutics CorporationRemodulin$772,207$281,42216 claims
PfizerEliquis$31$131,631110 claims
Boehringer IngelheimJardiance$36,057$99,82899 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →